IBS, A

BS….A

ND ABS?

GP

E

DU

CA

TI

ON

N

IG

HT

25

T

H

FE

B

20

15

DR

K

AT

RI

N

SJ

OQ

UI

ST

@O

NC

OD

OC

SY

DN

EY

(New trials, new drugs and good advice)

EVERYTHING OLD IS NEW AGAIN…

New treatments

Old treatments

Old news

New trials

NEW DRUGS

Some promising Regorafenib in advanced oesophago-gastric ca

‘OLD TREATMENTS’

Aspirin Beneficial in high risk groups as primary prevention

FAP, Lynch syndrome Latency period of 5+ years

Under investigation for secondary prevention ASCOLT study

Adding adjuvant aspirin vs placebo following completion of adjuvant treatment

AGITG/Australia participating

OLD NEWS (FOR SOME)?

Effect of exercise Evidence in other cancers

secondary prevention/breast CHALLENGE (CO21)

Structured exercise programme plus general health advice vs health advice only

Currently enrolling St George (TSH shortly) Medically fit colon cancer patients (high risk stage II and stage III)

completed adjuvant chemotherapy within the past 60-180 days. Current physical activity levels <recommended guidelines (>150 minutes of moderate-to-vigorous or >75 minutes of vigorous exercise/week).

ECHO Exercise during adjuvant chemotherapy for ovarian cancer

NEW TYPES OF TRIALS

One site, many diseases

Baskets, buckets & umbrellas

NEW TYPES OF TRIALS

Considering different targets within the one cancer type E.g. IMPACT – molecular targets in pancreas cancer

Considering common targets across different primary cancer types

Worldwide approaches – baskets, buckets & umbrellasAustralia – GCCTI www.gccti.org.au

“BASKET/BUCKET”

Evaluate effect of a single drug on a single mutation in a variety of cancers

Evaluate impact of different drugs on different mutations either in a single type of cancer or a variety of tumour types e.g. PARAGON (ANZGOG)

“UMBRELLA” TRIALS

PERSONALISED/PRECISION TRIALS

Tumours tested for ‘actionable’ mutations

Targeted vs ‘standard’ (e.g. MPACT)

QUESTIONS